1. Home
  2. BDSX vs JCE Comparison

BDSX vs JCE Comparison

Compare BDSX & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • JCE
  • Stock Information
  • Founded
  • BDSX 2005
  • JCE 2007
  • Country
  • BDSX United States
  • JCE United States
  • Employees
  • BDSX N/A
  • JCE N/A
  • Industry
  • BDSX Precision Instruments
  • JCE Trusts Except Educational Religious and Charitable
  • Sector
  • BDSX Health Care
  • JCE Finance
  • Exchange
  • BDSX Nasdaq
  • JCE Nasdaq
  • Market Cap
  • BDSX 257.0M
  • JCE 244.6M
  • IPO Year
  • BDSX 2020
  • JCE N/A
  • Fundamental
  • Price
  • BDSX $1.69
  • JCE $15.10
  • Analyst Decision
  • BDSX Strong Buy
  • JCE
  • Analyst Count
  • BDSX 4
  • JCE 0
  • Target Price
  • BDSX $3.08
  • JCE N/A
  • AVG Volume (30 Days)
  • BDSX 239.8K
  • JCE 49.7K
  • Earning Date
  • BDSX 11-05-2024
  • JCE 01-01-0001
  • Dividend Yield
  • BDSX N/A
  • JCE 9.26%
  • EPS Growth
  • BDSX N/A
  • JCE N/A
  • EPS
  • BDSX N/A
  • JCE N/A
  • Revenue
  • BDSX $60,902,000.00
  • JCE N/A
  • Revenue This Year
  • BDSX $48.06
  • JCE N/A
  • Revenue Next Year
  • BDSX $29.97
  • JCE N/A
  • P/E Ratio
  • BDSX N/A
  • JCE N/A
  • Revenue Growth
  • BDSX 46.25
  • JCE N/A
  • 52 Week Low
  • BDSX $1.15
  • JCE $11.64
  • 52 Week High
  • BDSX $2.21
  • JCE $14.28
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 44.40
  • JCE 49.52
  • Support Level
  • BDSX $1.66
  • JCE $14.91
  • Resistance Level
  • BDSX $1.80
  • JCE $15.51
  • Average True Range (ATR)
  • BDSX 0.08
  • JCE 0.19
  • MACD
  • BDSX -0.01
  • JCE -0.03
  • Stochastic Oscillator
  • BDSX 38.46
  • JCE 36.92

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities (the Options Strategy).

Share on Social Networks: